[go: up one dir, main page]

EP2637635A1 - Préparations cosmétiques et/ou dermatologiques comprenant des extraits d'algues des neiges - Google Patents

Préparations cosmétiques et/ou dermatologiques comprenant des extraits d'algues des neiges

Info

Publication number
EP2637635A1
EP2637635A1 EP10785009.1A EP10785009A EP2637635A1 EP 2637635 A1 EP2637635 A1 EP 2637635A1 EP 10785009 A EP10785009 A EP 10785009A EP 2637635 A1 EP2637635 A1 EP 2637635A1
Authority
EP
European Patent Office
Prior art keywords
skin
extract
protection
snow algae
algae extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10785009.1A
Other languages
German (de)
English (en)
Inventor
Sven Gohla
Daniel Stangl
Claudia Mundt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prairie Group AG
Original Assignee
Prairie Group AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prairie Group AG filed Critical Prairie Group AG
Publication of EP2637635A1 publication Critical patent/EP2637635A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9741—Pteridophyta [ferns]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • the present invention describes cosmetic or dermatological preparations containing snow algae extracts to achieve skin protection.
  • Cosmetic or dermatological preparations that aim to protect the skin are in principle not new.
  • cosmetic and dermatological compositions have been used several times to protect the skin, especially the human skin.
  • there is still a need to improve or modify skin protection because of changing environmental conditions as well as users' living conditions and habits.
  • the increased CO 2 emissions into the atmosphere cause a climate change that is accompanied by an increase in temperature. This has an impact on human skin, which requires more protection and also changed protection.
  • the changed living conditions mean that many people, especially in Western countries spend a long time of the day indoors. In the cold season, these rooms are heated and the air in the room is therefore usually very dry. The skin reacts with dehydration. Improved skin protection is required.
  • Snow algae extracts are extracts of snow algae extracted from Chlamydomonas spec. can be won. These extracts can be obtained from snow algae grown by the process of 2-phase cryo-culture. After culturing, a total extract can be prepared by high pressure homogenization using empty liposomes. Simultaneous drying and application of the extract to a support material by fluidized bed drying can complete the preparation of the extract.
  • the carrier material may for example consist of isomalt, lecithin, sodium benzoate, lactic acid and water in various proportions by weight.
  • the snow algae extract may, for example, be in powder form and have the following composition:
  • snow algae extracts obtained in this way are obtainable, for example, from the company Mibelle and have the name mibexol.
  • the snow algae are freshwater algae belonging to the genus Chlamydomonas.
  • the snow algae occur on snow and glacier surfaces in polar and alpine regions. Their mass increase is responsible for the green and red color of the snow; eg the blood snow.
  • the algae rest in the form of spores, often colored red, under the snow.
  • the spores turn into green, UV light-sensitive algae, which migrate to the surface of the snow. There, with the help of photosynthesis, the necessary energy is gained and multiplication begins.
  • nutrient limitation occurs again sporulation, ie the formation of red spores.
  • the red color stems from the incorporation of carotenoids (astaxanthin) for UV protection.
  • carotenoids (astaxanthin) for UV protection.
  • the living conditions of the snow algae are extreme, the temperatures are low, the UV radiation is strong and nutrients are scarce.
  • the snow algae must therefore feed on water, C0 2 , sunlight and minerals.
  • the optimal growth temperatures are 0 to + 5 ° C.
  • snow algae undergo a number of adaptations, detectable by the presence of various secondary metabolites, such as pigments (including carotenoids, eg astaxanthin), biopolymers (jellies), antifreeze proteins, antifreeze glycoproteins, and osmotically active amino acids and sugars.
  • Chlamydomonas extracts in cosmetic preparations has already been described in isolation.
  • EP 1437124 B1 describes a composition for acne treatment.
  • An algae extract obtained from the alga Chlamydomonas reinharhardtii is used together with other substances.
  • JP 2010013416 A discloses an algae extract of an alga belonging to the genus Chlamydomonas and having a hair growth promoting effect.
  • JP 2006028412 describes an extract of Chlamydomonas algae, preferably Chlamydomonas strain W80, which is used as an antioxidant.
  • antioxidant is disclosed in Abstract of JP 20021 14703 A. This antioxidant may i.a. be obtained from Chlamydomonas species.
  • the teachings of the prior art do not explicitly disclose the use of snow algae extracts nor their particular properties with respect to use in cosmetics or dermatology.
  • the object of the present invention is thus to provide cosmetic or dermatological preparations which ensure skin protection, in particular for human skin. This should be done in particular with regard to the changed environmental conditions.
  • the preparations should also be easy and problem-free to use.
  • This object is achieved by cosmetic and / or dermatological preparations containing snow algae extracts, and used to protect the skin.
  • cosmetic preparations containing snow algae extract for protecting the skin, in particular the human skin.
  • Preference according to the invention is given to cosmetic preparations for protecting the skin, in particular the human skin, which in addition to snow algae extract contain isomalt, lecithin, sodium benzoate, lactic acid and water.
  • the cosmetic and / or dermatological preparations have a concentration of snow algae extracts of 0.0001 to 99 wt .-%, preferably 0.0005 to 20 wt .-%, particularly preferably 0.001 to 10 wt .-%, based on the total weight of the preparation ,
  • the cosmetic or dermatological preparations containing snow algae extract may further comprise one or more of the following substances:
  • cosmetic preparations for protecting the skin in particular the human skin, which in addition to snow algae extract and one or more of the above substances also contain isomalt, lecithin, sodium benzoate, lactic acid and water.
  • the above preparations contain snow algae extract and one and / or several of the above substances together in a concentration of 0.0001 to 99 wt.%, Preferably 0.0005 to 20 wt.%, Particularly preferably 0.001 to 10 wt. based on the total weight of the preparation.
  • the invention furthermore relates to the use of snow algae extract in cosmetic preparations for protecting the skin, in particular for protection against modern strains. Also according to the invention is the use of snow algae extract and Isomalt, lecithin, sodium benzoate, lactic acid and water in cosmetic preparations for the protection of the skin, in particular for protection against modern strains.
  • snow algae extracts to protect the skin from the action of radicals.
  • use of snow algae extract to protect the skin from the effects of UV light According to the invention, the incorporation of snow algae extract in products that serve the UV protection of the skin. It can be achieved an increase in UV protection.
  • the use of snow algae extract to protect the skin enhances the longevity of the skin cells, thereby counteracting intrinsic and / or extrinsic skin aging.
  • the invention further provides a method for protecting the skin, in particular the human skin, wherein cosmetic and / or dermatological preparations containing snow algae extract are applied to the skin.
  • Also according to the invention is a method for protecting the skin, in particular the human skin, wherein cosmetic and / or dermatological preparations containing snow algae extract and isomalt, lecithin, sodium benzoate, lactic acid and water are applied to the skin.
  • snow algae extract and one or more of the following substances:
  • snow algae extract and one or more of the substances listed above together with isomalt, lecithin, sodium benzoate, lactic acid and water to protect the skin.
  • the use of snow algae extract and one or more of the substances listed above for the protection of the skin against modern loads, including the protection against the effects of radicals and UV light is included.
  • Next invention also includes the incorporation of snow algae extract and one or more of the substances listed above in products that serve the UV protection of the skin. It can be achieved an increase in UV protection.
  • the use of snow algae extract and one or more of the substances listed above to protect the skin is also inventive, wherein the protection is effected by increasing the longevity of the skin cells.
  • a method for protecting the skin in particular the human skin, wherein cosmetic and / or dermatological preparations containing snow algae extract and one or more of the substances listed above are applied to the skin.
  • a method for protecting the skin in particular the human skin, wherein cosmetic and / or dermatological preparations containing snow algae extract and one or more of the substances listed above are applied to the skin together with isomalt, lecithin, sodium benzoate, lactic acid and water ,
  • the preparations according to the invention are furthermore suitable for providing protection for the skin, in particular human skin, which protects the skin against stress effects. These stresses can be caused by radicals or compounds that are increasingly affecting human skin as pollution increases.
  • the preparations according to the invention are furthermore suitable for increasing the longevity of skin cells and thus of the skin. Longevity of skin cells gives the skin a longer life. This is desirable to counteract skin aging caused by intrinsic processes and / or extrinsic factors.
  • the invention includes the incorporation of snow algae extract and / or snow algae extract and one or more of the following substances:
  • the invention also includes the incorporation of snow algae extract and / or snow algae extract and one or more of the following substances:
  • snow algae extract and / or snow algae extract are incorporation of snow algae extract and one or more of the following substances:
  • the teaching of the present invention also describes cosmetic and / or dermatological preparations containing snow algae extracts and one or more of the following substances:
  • MPC Molecular Patch Complex
  • glycoprotein 1 and 2 and ginseng and horsetail extract may be referred to as GPVE.
  • the substances under a. and b. may be of marine or synthetic origin.
  • the collagen from a. may preferably be selected from collagens belonging to types 1, 3, 4 and 5.
  • the chitosans under b. may preferably comprise chitosans having a molecular weight of about 80,000 to 15,000,000 g / mol.
  • the chitosans can be obtained from insects and / or crustaceans.
  • glycosylaminoglycans under c. may preferably comprise chondroitin-4-sulphate and / or chondroitin-6-sulphate.
  • the peptide or peptides under d. may be preferably selected from peptides that are similar to cell growth factors or that respond to cell growth factors. Preference is given to a peptide with the INCI name oligopeptide-21. This peptide is available, for example, from Caregen Co., Ltd., Korea under the trade name IDP-4. This oligopeptide-21 or at least a portion of oligopeptide-21, the portion that binds to skin cell receptors, may be present.
  • the peptide under d. is preferably in a form which provides direct contact with a., b. and c. and e., if any, prevented. The most preferred form is the presence of d. in the form of a nanoemulsion.
  • WO 2010/086754 is hereby incorporated by reference in its entirety in the disclosure of this application.
  • the cosmetic or dermatological preparations according to the invention can be present in the customary cosmetic and / or dermatological pharmaceutical preparation forms, preferably as gel, O / W emulsion, W / O emulsion, W / O emulsion, microemulsion, cosmetic stick.
  • the cosmetic or dermatological products of the invention may be in the form of the usual cosmetic and / or dermatological product forms, preferably as an aqueous surfactant-containing preparation, emulsion, ointment. Cream, gel, powder, mask, foam preparation and aerosol preparation are present.
  • the preparations according to the invention are furthermore suitable for the preparation of sunscreen products.
  • Sunscreen products are characterized by a content of UV filters that protect the skin from the harmful effects of sunlight.
  • the preparations according to the present invention preferably contain at least one UV-A, UV-B and / or broad-spectrum filter substance.
  • the formulations may, although not necessary, optionally also contain one or more organic and / or inorganic pigments as UV filter substances, which may be present in the water and / or the oil phase.
  • the preparations according to the present invention may furthermore advantageously also be in the form of so-called oil-free cosmetic emulsions which contain a water phase and at least one UV filter substance which is liquid at room temperature as further phase and which, in particular, can also be free of further oil components.
  • Preferred inorganic pigments are metal oxides and / or other water-insoluble or insoluble metal compounds, in particular oxides of titanium (TiO 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon ( Si0 2 ), manganese (eg MnO), aluminum (Al 2 0 3 ), cerium (eg Ce 2 0 3 ), mixed oxides of the corresponding metals and mixtures of such oxides and the barium sulfate (BaS0 4 ).
  • the pigments can also be used advantageously in the form of commercially available oily or aqueous predispersions.
  • dispersants and / or solubilizers can be added to these predispersions.
  • the pigments may advantageously be surface-treated ("coated"), in which case a hydrophilic, amphiphilic or hydrophobic character is to be formed or retained, for example or hydrophobic inorganic and / or organic layer
  • a hydrophilic, amphiphilic or hydrophobic character is to be formed or retained, for example or hydrophobic inorganic and / or organic layer
  • the various surface coatings may also contain water for the purposes of the present invention.
  • Suitable titanium dioxide particles and predispersions of titanium dioxide particles are available from the following companies under the following trade names:
  • UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which has been sold by Givaudan under the trademark Parsol ® 1789 and sold by Merck under the trade name Eusolex® 9020.
  • Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself with the INCI name phenylbenzimidazole sulfonic acid (CAS No. 27503-81 -7), which is available, for example, under the trade name Eusolex 232 from Merck or under Neo Heliopan Hydro from Symrise;
  • Benzene 1, 4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) is called.
  • Benzene 1, 4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) has the INCI name Terephtalidene Dicampher sulfonic acid (CAS.-No .: 90457-82-2) and is, for example, under the trade name Mexoryl SX of available from Chimex;
  • Sulfonic acid derivatives of 3-Benzylidencamphers such as. B. 4- (2-oxo-3-bornylidenme- thyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and salts thereof.
  • Benzoxazole derivatives such as.
  • Hydroxybenzophenones e.g. B. 2- (4'-diethylamino-2'-hydroxybenzoyl) -benzoeklar (also: aminobenzophenone), which is available under the trade name Uvinul A Plus in the company. BASF.
  • Triazine derivatives such as. B. 2,4-bis - ⁇ [4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine (INCI: Bis- Ethylhexyloxylphenol methoxyphenyl triazine), which is available under the trade name Tinosorb® S from CIBA-Chemikalien GmbH; Dioctylbutylamidotriazone (INCI: Diethylhexyl Butamido Triazone), which is available under the trade name UVASORB HEB from Sigma 3V; 4,4 ' ! 4 "- (!
  • Benzotriazoles such as. B. 2,2'-methylene-bis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol) (INCI: Methylene bis-benztriazolyl tetramethylbutylphenol ), which z. B. under the trade name Tinosorb® M at CIBA-Chemikalien GmbH is available.
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably (2-ethylhexyl) 4- (dimethylamino) benzoate, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of benzalmalonic acid preferably di (2-ethylhexyl) 4-methoxybenzalmalonate
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone and
  • Particularly advantageous preparations in the sense of the present invention which are distinguished by a high or very high UV-A protection, preferably contain further UV-A and / or broadband filters, in particular dibenzoylmethane derivatives, in addition to the filter substance (s) according to the invention.
  • UV filters which can be used in the context of the present invention is of course not intended to be limiting.
  • the total amount of the filter substances is from the range of 0.1 to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular 1, 0 to 6.0 wt .-% - each based on the total weight of the preparations - chosen to provide cosmetic preparations that protect the hair or the skin from the entire range of ultraviolet radiation.
  • the cosmetic preparations according to the invention may contain cosmetic adjuvants, such as are commonly used in such preparations, for.
  • preservatives preservatives, complexing agents, bactericides, perfumes, substances to increase the foaming, dyes, pigments that have a coloring effect, thickeners, moisturizing and / or moisturizing substances, fillers that improve the feel of the skin, fats, oils, waxes or other common ingredients of a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • Advantageous preservatives for the purposes of the present invention are, for example, iodopropylbutylcarbamates (for example those available under the trade names Glycacil-L, Glycacil-S from Lonza and / or Dekaben LMB from Jan Dekker), parabens (ie p-hydroxybenzoic acid alkyl esters, such as Methyl, ethyl, propyl and / or butylparaben), phenoxyethanol, ethanol, benzoic acid and the like.
  • the preservation system according to the invention also advantageously also preserving aids, such as octoxyglycerol, glycine soy etc.
  • EDTA [S, S] -Ethylendiamindisuccinat
  • EDDS EDTA
  • Octaquest from the company Octel
  • pentasodium ethylenediamine tetramethylene phosphonate which z. B. under the trade name Dequest 2046 from the company.
  • Monsanto is available and / or iminodisuccinic which u. a.
  • Bayer AG under the trade names Iminodisuccinat VP OC 370 (about 30% solution) and Baypure CX 100 is permanently available.
  • compositions are also obtained when antioxidants are used as additives or active ingredients.
  • the preparations advantageously contain one or more antioxidants.
  • antioxidants all suitable or common for cosmetic applications antioxidants can be used.
  • water-soluble antioxidants can be used, such as vitamins.
  • antioxidants are vitamin E and its derivatives as well as vitamin A and its derivatives.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt .-%, particularly preferably 0.05 to 20 wt .-%, in particular 0.1 to 10 wt .-%, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant (s)
  • beneficial agents to be used in the context of the present invention are those which have a positive effect on the condition of the skin, in particular active ingredients for positive influence on the aging skin, which reduce the development of wrinkles or existing wrinkles.
  • biochinones in particular ubiquinone (Q10) and ubiquinol, folic acid and its derivatives (in particular tetrahydrofolic acid and dihydrofolic acid), niacin and its derivatives (in particular niacinamide), creatine and creatinine, carnitine, biotin, isoflavone, cardiolipin, lipoic acid, anti Freezing proteins, hop and hop malt extracts.
  • agents that promote the restructuring of connective tissue such as natural and / or synthetic isoflavonoids and isoflavonoid-containing plant extracts - such.
  • soy and clover extracts - can be used very well in the formulations of the invention.
  • the formulations are particularly suitable as active ingredients for supporting the skin functions in dry skin (such as, for example, vitamin C, biotin, carnitine, propionic acid, green tea extracts, eucalyptus oil, urea and mineral salts (such as, for example, NaCl, Marine minerals) as well as osmolytes (such as inositol, betaine, quaternary ammonium compounds)).
  • active ingredients for relief or positive proved, for example, vitamin C, biotin, carnitine, propionic acid, green tea extracts, eucalyptus oil, urea and mineral salts (such as, for example, NaCl, Marine minerals) as well as osmolytes (such as inosito
  • Influencing of irritative skin conditions be it with sensitive skin in general or irritated by noxious skin (UV light, chemicals), as beneficial.
  • agents such as sericosides, various extracts of licorice, licochalcone, especially licochalcone A, silymarin, silyphos, dexpanthenol, inhibitors of prostaglandin metabolism, in particular cyclooxygenase and the leukotriene metabolism, in particular 5-lipoxygenase, but also 5-lipoxvgenase Inhibitor protein, FLAP.
  • creatine and creatinine are suitable active ingredients to create and / or renew an (energy) depot and to activate the repair of various cellular structures, in particular the DNA.
  • modulators of pigmentation also proved to be advantageous.
  • agents that reduce the pigmentation of the skin and thus lead to a cosmetically desired lightening of the skin and / or reduce the occurrence of age spots and / or lighten existing age spots include tyrosine sulfate, dioic acid (8-hexadecene-1, 16-dicarboxylic acid) and lipoic acid and lipoamide, various extracts of licorice, kojic acid, hydroquinone, arbutin, alpha-arbutin, deoxyarbutin, fruit acids, especially alpha-hydroxy acids (AHAs ), Bearberry (Uvae ursi), ursolic acid, ascorbic acid, green tea extracts, aminoguanidine, pyridoxamine, niacinamide, inhibitors of Proteinase Activated Receptor 2 (PAR-2).
  • PAR-2 Proteinase Activated Receptor 2
  • formulations according to the invention which contain other active ingredients which bring about increased or faster tanning of the skin (advanced glycation end products (AGE), lipofuscins, nucleic acid oligonucleotides, purines and pyrimidines, NO-releasing substances), tyrosine and its derivatives (in particular N Acetyl-tyrosine), phenylalanine and its derivatives (especially N-acetyl-phenylalanine), activators of the Proteinase Activated Receptor 2 (PAR-2), either with or without the influence of UV light.
  • active ingredients which bring about increased or faster tanning of the skin
  • AGE glycation end products
  • lipofuscins nucleic acid oligonucleotides
  • purines and pyrimidines purines and pyrimidines
  • NO-releasing substances NO-releasing substances
  • tyrosine and its derivatives in particular N Acetyl-tyrosine
  • Inventive formulations which z. B. known anti-wrinkle active ingredients such as Flavonglyco- side (especially ⁇ -glycosyl rutin), coenzyme Q10, vitamin E and / or derivatives and the like, are particularly advantageous for the prophylaxis and treatment of cosmetic or dermatological lesions, as z. Eg skin aging (such as dryness, roughness and formation of dryness lines, itching, reduced refatting (eg after washing), visible vascular dilation (telangiectasia, cuperosis), slackness and development of wrinkles and wrinkles, local hyper-, hypo- and false pigmentation (eg age spots), increased susceptibility against mechanical stress (eg cracking) and the like). Furthermore, they are advantageously suitable against the appearance of dry or rough skin.
  • known anti-wrinkle active ingredients such as Flavonglyco- side (especially ⁇ -glycosyl rutin), coenzyme Q10, vitamin E and / or derivatives and the like, are particularly advantageous for the
  • Moisturizers are substances or mixtures of substances which give cosmetic preparations the property of reducing the moisture release of the horny layer (also called transepidermal water loss (TEWL) after application or spreading on the skin surface and / or positively influencing the hydration of the horny layer ,
  • TEWL transepidermal water loss
  • moisturizers for the purposes of the present invention are, for example, glycerol, lactic acid and / or lactates, in particular sodium lactate, butylene glycol, propylene glycol, biosaccharide gum-1, glycine soya, ethylhexyloxyglycerol, pyrrolidonecarboxylic acid and urea.
  • the preparations according to the invention may further comprise one or more substances which may be selected from amino acids, ⁇ -biotin, (NH 4 ) 6 Mo 7 024, adenine, AICI 3, biotin, CaCl 2 , calcium pantothenate, choline chloride, CoCl 2 , CrK (S0 4 ) 2 , CuS0 4 , D-Ca pantothenate, E DTA.
  • substances which may be selected from amino acids, ⁇ -biotin, (NH 4 ) 6 Mo 7 024, adenine, AICI 3, biotin, CaCl 2 , calcium pantothenate, choline chloride, CoCl 2 , CrK (S0 4 ) 2 , CuS0 4 , D-Ca pantothenate, E DTA.
  • the amino acids include L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-cystine, glycine, L-glutamine, L-glutamic acid, L-histidine, L-isoleucine, L-leucine, L Lysine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.
  • One or more amino acids can be selected.
  • the amino acids may be present, for example, as L-lysine and / or lysine-HCl.
  • the preparations according to the invention can furthermore contain additives of one or more cell culture media for skin cell culture.
  • Examples are DMEM / HAM F12 (1: 1) and / or MCDB 153.
  • the preparation may further comprise citrate buffer and / or Q10 and / or alpha-glycosylrutin and / or Zn orotate and / or carnitine and taurine and / or one or more alpha hydroxy acids.
  • the oil phase of the preparations according to the present invention advantageously contains nonpolar, for example those which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular mineral oil, Vaseline (petrolatum), paraffin oil, squalane, polyolefins, hydrogenated polyisobutenes and Isohe - xadecan.
  • nonpolar for example those which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular mineral oil, Vaseline (petrolatum), paraffin oil, squalane, polyolefins, hydrogenated polyisobutenes and Isohe - xadecan.
  • polyolefins polydecenes are the preferred substances.
  • the oil phase may further comprise a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Silicone oils are synthetic compounds in which silicon atoms via oxygen atoms chain and / or net-like linked and the remaining valences of silicon by hydrocarbon radicals (usually methyl, more rarely ethyl, propyl, phenyl groups, etc.) are saturated , Systematically, the silicone oils are called polyorganosiloxanes.
  • the methyl sub- substituted polyorganosiloxanes which are the quantitatively most important compounds of this group and are characterized by the following structural formula
  • CH 3 CH 3 CH 3 are also referred to as polydimethylsiloxane or dimethicone (INCI). Dimethicones are available in different chain lengths or with different molecular weights.
  • cyclomethicone octamethylcyclotetrasiloxane
  • silicone oils are also advantageous for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Particularly advantageous polyorganosiloxanes in the context of the present invention are, for example, dimethylpolysiloxanes [poly (dimethylsiloxane)], which are obtainable, for example, under the trade names Abil 10 to 10 000 from Th. Goldschmidt.
  • phenylmethylpolysiloxanes INCI: phenyl dimethicone, phenyl trimethicone
  • cyclic silicones octamethylcyclotetrasiloxane or decamethylcyclopentasiloxane
  • amino-modified silicones INCI: amodimethicones
  • silicone waxes eg.
  • polysiloxane-polyalkylene copolymers ICI: stearyl dimethicone and cetyl dimethicone
  • dialkoxydimethylpolysiloxanes stearoxy dimethicones and behenoxy stearyl dimethicone
  • cetyl dimethicone hexamethylcyclotrisiloxane
  • polydimethylsiloxane poly (methylphenylsiloxane).
  • the preparations according to the present invention may also advantageously contain one or more substances from the following group of siloxane elastomers, for example in order to increase the water resistance and / or the sun protection factor of the products:
  • R are each independently hydrogen, Ci-24-alkyl (such as methyl, ethyl, propyl) or aryl (such as phenyl or To- lyl), alkenyl (such as vinyl) and the weight ratio of the units R 2 SiO 2 to RSiOi , 5 is selected from the range of 1: 1 to 30: 1;
  • siloxane elastomers which are insoluble and swellable in silicone oil obtainable by the addition reaction of an organopolysiloxane (1) containing silicon-bonded hydrogen with an organopolysiloxane (2) containing unsaturated aliphatic groups,
  • the amounts used are such that the amount of hydrogen of the organopolysiloxane (1) or the unsaturated aliphatic groups of the organopolysiloxane (2)
  • the siloxane elastomer (s) are in the form of spherical powders or in the form of gels.
  • siloxane elastomers are those with the INCI name dimethicone / vinyl dimethicone crosspolymer, for example that available from DOW CORNING under the trade names DOW CORNING 9506 Powder available.
  • siloxane elastomer is used in combination with oils of hydrocarbons of animal and / or vegetable origin, synthetic oils, synthetic esters, synthetic ethers or mixtures thereof.
  • siloxane elastomer is used in combination with unbranched silicone oils or cyclic silicone oils or mixtures thereof which are liquid or pasty at room temperature.
  • organopolysiloxane elastomers with the INCI name Dimethicone / Polysilicone-1 1, in particular the Gransil types GCM, GCM-5, DMG-6, CSE gel, PM gel, LTX available from Grant Industries Inc. ININ gel, AM-18 gel and / or DMCM-5.
  • the usual packaging suitable as they are used in cosmetics or dermatology application.
  • Bag-on-valve systems consisting of a valve which is hermetically sealed to a foil bag.
  • the foil bag is optimally multi-layered with at least one or more barrier layers.
  • the bag valve is hermetically sealed before being filled with an aerosol container (aluminum, tinplate or plastic).
  • the bag In the so-called bag-in-can system, the bag is located in an aerosol container and is connected to the valve and the aerosol container when closing.
  • the container is preferably supplied with environmentally friendly propellant gases, such as nitrogen or noble gases, wherein the propellant gas between the bag and sealed aerosol container is, whereas the cosmetic is in the bag.
  • environmentally friendly propellant gases such as nitrogen or noble gases
  • the mode of operation of the bag-in-can systems or bag-on-valve systems can be described as follows: the propellant surrounds the bag filled with the cosmetic.
  • the nozzle When the nozzle, the spray or application head of the system, is depressed, the pressure on the bag will cause the contents to leak in varying amounts depending on the diameter of the nozzle.
  • the preparation contained in the bag must be matched to the packaging in order to achieve the correct output in terms of viscosity at a given can pressure.
  • the advantage of the two-chamber technology (bag-in-can systems, bag-on-valve systems) is that no contamination and thus no air can penetrate into the bag under pressure.
  • the dispensing head optimally includes a closing mechanism at the exit opening which reduces potential contamination of the product between the valve opening and the exit opening.
  • the self-closing dispensing head can z. B. be executed as follows:
  • an aerosol valve By actuating the applicator, an aerosol valve is opened, the product flows through a channel to the outlet opening.
  • the elastic element eg made of a thermoplastic elastomer (TPE), polyethylene, polypropylene, polyoxymethylene (POM)
  • TPE thermoplastic elastomer
  • POM polyoxymethylene
  • Thesverschliessende dispensing head may also z. B. be carried out as follows:
  • an aerosol valve By actuating the applicator, an aerosol valve is opened, an elastic membrane springs opposite to the product flow. An inseparable plug connected to the membrane follows this movement and the exit port / ring slit nozzle is opened.
  • the MTT test the compatibility of snow algae extracts was demonstrated.
  • keratinocytes were incubated with various concentrations of snow algae extract for 12 hours.
  • the cell vitality was determined by the MTT test.
  • MTT test a mitochondrial dehydrogenase in living cells cleaves the tetrazolium ring of the pale yellow substance MTT (3- (4,5-dimethylthiazolyl) -2,5-diphenyltetrazolium bromide). It produces dark blue formazan crystals, which are accumulated in intact cells. The cells are lysed and the crystals released.
  • FIG. 1 shows the results of treatment of HaCaT cells (spontaneous immortalized keratinocytes), NIH3T3 fibroblasts and mesenchymal stem cells (MSC) with snow algae extracts and determination of cell vitality. There is no toxic effect on snow algae extract treatment of these cell types.
  • the antioxidant activity of snow algae extracts was determined by two different test methods.
  • the measurement of the antioxidant capacity is based on a redox reaction between a test substance, here snow algae extract, and copper II (Cu (II)).
  • Cu (II) is converted to Cu (I).
  • Cu (I) is detected by the addition of bathocuproine.
  • the photometric measurement takes place at 490 nm.
  • the results of this test are shown in FIG. 2a. The reducing power of snow algae extract at various concentrations becomes apparent.
  • the capacity of a substance to absorb oxygen radicals is determined in the ORAC (oxygen radical absorbance capacity) test.
  • ORAC oxygen radical absorbance capacity
  • the ability of a test substance to inhibit the oxidation of a fluorophore, usually fluorescein, by a strong oxidant is determined.
  • the strong oxidant is 2,2'-azobis (2-amidino-propane).
  • the course of the reaction is monitored by measurements at 535 nm.
  • Trolox is used as standard.
  • Trolox is a water-soluble vitamin E derivative and has a pronounced antioxidant capacity and is therefore used as a reference substance.
  • the standard curve is obtained by plotting the various Trolox concentrations against the mean of the area determinations of two measurements for each concentration.
  • the net area under the curve (AUC) of the samples and the standard solutions in different concentrations is determined.
  • the net area values are obtained from the difference of the sample area values or standard area values and the area value below the zero value. The determination of the zero value takes place without addition of sample or standard.
  • the ORAC values of the samples are given as ⁇ Trolox equivalents per liter.
  • the results of the ORAC test for snow algae extract are shown in Figure 2b.
  • the upper part of the figure shows that snow algae extract has a good antioxidant power down to low concentration ranges (0.03%).
  • comparisons were made with resveratol.
  • Resveratol is a phytoalexin and belongs to the polyphenols. It was first isolated in 1963 from Japanese Knotweed. This substance has strong antioxidant properties.
  • the results in the lower part of Fig. 2b show a good antioxidant activity for snow algae extract, but does not quite come close to the efficacy of resveratol.
  • mtDNA mitochondrial DNA
  • the most common mutation is a deletion of 4,977 bp, including the called common deletion.
  • This mutation can be detected by a test using PCR (common deletion assay). Keratinocytes were grown and treated with snow algae extract (0.05%) for 48 hours. After replacing the cell culture medium with PBS solution, the cells were irradiated with UVB light (1.5 mJ / cm 2 ). This was followed by a one-hour incubation in cell culture medium at 37 ° C. The cells were harvested, the DNA extraction was carried out with a QiagenKit. For the PCR 2-5 ng of DNA were used.
  • GADD45A is the abbreviation for Growth arrest and DNA-damage-inducible protein alpha. Even after treatment with DNA-damaging substances, the transcription rate of the GADD45A gene is increased. The transcription rate of GADD45A can be detected by PCR reactions ( Figure 4).
  • Fibroblasts and keratinocytes were treated with 1% and 3% snow algae extract or ascorbate for 2 hours, respectively. Control cells were not treated. Subsequently, the cells were exposed to a stress factor in the form of H 2 0 2 (150 ⁇ ). At various times the cells were harvested and the RNA isolated. Starting from the RNA, cDNA was synthesized which served as template for the PCR. As primers for the PCR, those specific for the GADD45A transcript were used. The PCR products were separated in an agarose gel and quantified with the Geliance 200 Imaging System (Perkin Elmer). The amplification band of the analyzed transcript was normalized with the amplification band of a standard 18S transcript. The values thus obtained were indicated as percentages in FIG.
  • the untreated controls corresponded to 100% values.
  • fibroblasts no increase in GADD45A transcripts is observed under control conditions.
  • more GADD45A transcripts are detectable in the cells treated with snow algae extract or with ascorbate than in the control cells.
  • snow algae extract in a concentration of 3% causes an increased rate of GADD45A transcripts (58%) and thus increases the protection for the cells.
  • the non-stressed, untreated cells also showed an increased transcription rate of GAdd45A after exposure to snow algae extract. Transcription is significantly enhanced (79%, in 3% snow algae extract) under stress conditions. This shows that snow algae extract is capable of activating protective mechanisms in skin cells, especially under stress conditions.
  • sirtuin transcripts were detected.
  • Sirtuins are enzymes that deacetylate histone proteins. As a result, lysine residues are released and the nitrogen atom in the amine residue of this amino acid condenses more strongly with the DNA. As a result, transcription processes are disturbed or prevented.
  • sirtuins also show ADP-ribosyltransferase activity, and in addition to the histones, a number of other proteins are also being modified, demonstrating an influence on cell aging and attempts to detect sirtuin transcripts
  • primers for the detection of sirtuin transcripts in the PCR reaction were specific for sirtuin 1 (sirt 1) and sirtuin 6 (sirt6), respectively, and the evaluation and presentation were carried out in the same way
  • sirtuin 1 sirt 1
  • sirt6 sirtuin 6
  • the transcription rate in fibroblasts incubated with snow algae extract increased by 18% and sirtuin 6 by 18% and sirtuin 6, respectively, by 28% compared to untreated cells the transcription rate of sirtuin 1 by 14% and of sirtuin 6 by 27% by the action of snow algae extract compared to unbehan damaged cells.
  • phase 1 For use 7 ml of phase 1 are mixed with 1 ml of phase 2.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des préparations cosmétiques ou dermatologiques, qui contiennent des extraits d'algues des neiges et une ou plusieurs autres substances, qui sont appropriées pour obtenir une protection de la peau.
EP10785009.1A 2010-11-12 2010-11-12 Préparations cosmétiques et/ou dermatologiques comprenant des extraits d'algues des neiges Withdrawn EP2637635A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/067341 WO2012069073A1 (fr) 2010-11-12 2010-11-12 Préparations cosmétiques et/ou dermatologiques comprenant des extraits d'algues des neiges

Publications (1)

Publication Number Publication Date
EP2637635A1 true EP2637635A1 (fr) 2013-09-18

Family

ID=44202324

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10785009.1A Withdrawn EP2637635A1 (fr) 2010-11-12 2010-11-12 Préparations cosmétiques et/ou dermatologiques comprenant des extraits d'algues des neiges

Country Status (3)

Country Link
US (1) US20130287714A1 (fr)
EP (1) EP2637635A1 (fr)
WO (1) WO2012069073A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014216022A1 (de) 2013-08-16 2015-02-19 La Prairie Group Ag Zubereitung zum Schutz vor extrinsischer und intrinsischer Hautalterung
US9763873B2 (en) 2013-08-16 2017-09-19 La Prairie Group Ag Preparation for protecting against extrinsic and intrinsic skin aging
DE102013222168A1 (de) 2013-10-31 2015-04-30 La Prairie Group Ag Verbesserter Schutz vor extrinsischer Hautalterung
GB2524268A (en) * 2014-03-18 2015-09-23 Univ Surrey Pathogenic infections
JP6720074B2 (ja) * 2014-04-28 2020-07-08 三井製糖株式会社 外用組成物
CN104940121B (zh) * 2015-07-08 2017-10-24 广州丽丰化妆品制造有限公司 一种极地雪融霜及其制备方法
US9925137B2 (en) 2015-08-19 2018-03-27 Maple Mountain Group, Inc. Skin rejuvenation and defense system
WO2017069157A1 (fr) 2015-10-20 2017-04-27 ロート製薬株式会社 Composition topique pour la peau
DE102017213232A1 (de) 2017-08-01 2019-02-07 Beiersdorf Ag 2-Propylheptylocanoat in kosmetischen Zubereitungen
CN108078856A (zh) * 2018-01-18 2018-05-29 凌中鑫 一种小分子肽面膜布及其生产方法
CH714167B1 (de) * 2018-02-01 2019-03-15 La Prairie Group Ag Wirkstoffkomplex für kosmetische Zubereitungen.
EP3755301A1 (fr) * 2018-02-21 2020-12-30 Act + Acre, Inc. Appareil, procédés et systèmes de traitement à faible énergie de produits de consommation d'hygiène personnelle ; formulations de ceux-ci
IT201800004350A1 (it) * 2018-04-10 2019-10-10 Preparato cosmetico
CN110664644B (zh) * 2019-09-25 2022-05-17 北京斯利安药业有限公司 一种含叶酸的护肤组合物、精华及其制备方法
CN110585247A (zh) * 2019-09-25 2019-12-20 佛山职业技术学院 极地雪藻细胞裂解物在制备预防、延缓或治疗皮肤老化的药物或化妆品中的应用
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
CN112876683B (zh) * 2021-02-04 2022-04-22 浙江大学 一种八丁香酚环氧基液体笼型倍半硅氧烷及其制备方法和应用
EP4140471A1 (fr) * 2021-08-31 2023-03-01 The Boots Company plc Composition avec un agent biologiquement actif
KR20250010055A (ko) * 2022-06-15 2025-01-20 더 프록터 앤드 갬블 캄파니 국소 피부 케어 조성물
EP4538373A1 (fr) 2023-10-13 2025-04-16 AXAGARIUS GmbH & Co. KG Isolement d'acides nucléiques à partir d'échantillons biologiques

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191489B (en) * 1983-10-12 1987-02-27 Bodnarne Lovasi,Beatrix,Hu Cosmetic containing living unicellular alga
FR2728467B1 (fr) * 1994-12-21 1998-10-16 Codif International Sa Produit cosmetique a base d'extraits proteiques naturels d'algues
FR2787027B1 (fr) * 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20020045600A1 (en) * 1999-07-08 2002-04-18 Schwarzman Laura M. Topical skin treatment for sea lice, insect bites and skin irritation
JP2002114703A (ja) * 2000-10-06 2002-04-16 Yamaki:Kk 抗酸化剤
FR2849596B1 (fr) * 2003-01-08 2005-02-11 Oreal Composition pour le traitement d'une peau a tendance acneique
WO2004071519A1 (fr) * 2003-01-14 2004-08-26 Bruneau Francois Micro-organismes photosynthetiques enrichis en molecules biologiquement actives, leurs procedes de preparation, et leurs utilisations
EP1635782A1 (fr) * 2003-05-24 2006-03-22 JUVENA (International) AG Milieux de culture de tissus utilises comme composants de cosmetiques
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
US20060018867A1 (en) * 2004-05-12 2006-01-26 Ichimaru Pharcos Co., Ltd Cosmetic composition and production thereof
JP2006028412A (ja) * 2004-07-20 2006-02-02 Kansai Electric Power Co Inc:The 緑藻由来の抗酸化剤
SE529064C2 (sv) * 2005-01-03 2007-04-24 Selectica Pharmaceuticals Ab Topiska kompositioner
DE102005031364A1 (de) * 2005-06-30 2007-01-11 Ernst-Moritz-Arndt-Universität Greifswald Nahrungsergänzungsmittel mit verbesserten antioxidativen Eigenschaften
US20070026085A1 (en) * 2005-07-26 2007-02-01 Global Life Technologies Corp. Antimicrobial and antiviral composition
BRPI0600941A (pt) * 2006-03-30 2007-11-20 Botica Com Farmaceutica S A nanoemulsão, método de produção e composição cosmética e dermatológica contendo a mesma
WO2008005533A2 (fr) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions et procédés de modification génétique de cellules ayant une fonction cosmétique pour l'amélioration de l'aspect cosmétique
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
WO2009016133A1 (fr) * 2007-07-27 2009-02-05 Cargill, Incorporated Micronisation de polyols
TWI477291B (zh) * 2008-01-15 2015-03-21 Amorepacific Corp 使用冰河水萃取之方法及其萃取物，以及含有具有封入該萃取物之奈米乳化顆粒或冰河水之化妝品組成物
JP2010013413A (ja) * 2008-07-07 2010-01-21 Maruzen Pharmaceut Co Ltd 美白効果を有する藻類エキス
KR101199580B1 (ko) * 2008-08-06 2013-11-27 (주)에델프라우 국소 투여용 나노에멀젼
EP2391424B1 (fr) * 2009-01-30 2016-12-28 Beiersdorf AG Préparation cosmétique ou dermatologique comprenant un peptide favorisant la croissance cellulaire et un complexe cellulaire
CH701253A1 (de) * 2009-06-12 2010-12-15 Mibelle Ag Verwendung eines Extraktes aus Schneealgen in kosmetischen oder dermatologischen Formulierungen.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012069073A1 *

Also Published As

Publication number Publication date
WO2012069073A1 (fr) 2012-05-31
US20130287714A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
EP2637635A1 (fr) Préparations cosmétiques et/ou dermatologiques comprenant des extraits d'algues des neiges
EP2247949B1 (fr) Procédé de sélection d'antioxydants pour une utilisation dans des compositions appliquées topiquement
EP2514403A1 (fr) Composition cosmétique permettant d'augmenter la synthèse de collagène dans les cellules de la peau
EP1670488B1 (fr) Procede pour appliquer de l'oxygene sur la peau
EP2319586A1 (fr) Utilisation de préparations cosmétiques comprenant de l'oxygène libre non lié moléculairement
JP6186105B2 (ja) 単糖と日焼け止め剤との組合せ及びその美容的使用
US20160296438A1 (en) Protective action of lutein against blue light on human skin cell lines
CN101663020A (zh) 基于无机-有机混合体系的uv光保护制剂
EP1932513A2 (fr) Compositions destinées à l'amélioration de l'aspect optique de la peau
EP4018994A1 (fr) Composition comprenant des huiles, des acides gras libres et du squalène
EP1388338B1 (fr) Compositions anti-solaires moussables
WO2018215219A1 (fr) Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile
EP1861170A1 (fr) Utilisation de preparations cosmetiques contenant une quantite d'oxygene libre non lie moleculairement
EP1861171A1 (fr) Utilisation de preparations cosmetiques presentant une teneur en oxygene libre sans liaison moleculaire
JP2006036704A (ja) 日焼け止め用化粧品
EP1473026A1 (fr) Bâton cosmétique contenant un agent auto-bronzant
WO2007101882A1 (fr) Oligopeptide substitue par de la tropolone et de l'hydroxybenzol pour depigmentation
EP1721600A1 (fr) Kit de protection solaire et méthode d'ajustement de la pigmentation
EP1890775A1 (fr) Preparations cosmetiques presentant une certaine teneur en extrait aqueux d'anis et en agents emulsifiants non ioniques specifiques
WO2011158041A2 (fr) Composition topique
WO2024114951A1 (fr) Composition d'écran solaire
DE10355541A1 (de) Hauttönungsprodukt
HK1148070A (en) Method of selecting antioxidants for use in topically applied compositions
HK1148070B (en) Method of selecting antioxidants for use in topically applied compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150602